KMT2A and leukemia: JNJ-75276617 (Bleximenib) is a novel potent inhibitor of the protein–protein interaction between Menin and KMT2A; in KMT2A-rearranged and NPM1-mutant leukemia cells, this compound inhibited the interaction of the Menin–KMT2A complex with chromatin at the level of target genes, resulting in the reduced expression of several target genes such as MEIS1 and FLT3 and exerted potent antiproliferative activity [110].